"At Zimbis, we're driven by the opportunity to make complex operations simpler for dental laboratories," said Louis Visser, President Zimbis. "By partnering with Argen, we're giving labs access to ...
The antibody experts at arGEN-X have teamed up with dermatology-focused biotech Leo Pharma on a treatment for inflammatory skin diseases, inking a deal worth up to $116 million. Under the agreement, ...
Breda, the Netherlands/Ghent, Belgium and Ballerup, Denmark – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated ...
ARGEN is a patented light scattering instrument that addresses key research and development issues in the biopharmaceutical industry by providing real-time stability monitoring, manufacturing stress ...
The facility will operate under arGEN-X’ CSO Prof. Dr. Hans de Haard, and CDO Dr. Torsten Dreier, who have already attracted an experienced international core team of antibody discovery and ...
LONDON – "This window really is unique: It's supporting relatively early stage stories and especially platform technology stories." So said Tim Van Hauwermeiren, CEO of antibody specialist Argen-x BV, ...
RuiYi (formerly Anaphore) negotiated a worldwide exclusive license to ArGEN-X’ preclinical anti-IL-6 monoclonal antibody ARGX-109, which is in development as a potential treatment for oncology and ...
Argen launched the products in Canada on April 25 and in the U.S. on May 20. The S5 is a five-axis dental milling machine capable of both dry and wet operation. It is ideal for users seeking the ...
Firm will combine fucose-removal technology with in-house camelid-based Simple platform for therapeutic antibodies. arGEN-X negotiated a nonexclusive license to BioWa’s Potelligent® monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results